KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bausch Health Companies (BHC) EBITDA (2016 - 2025)

Historic EBITDA for Bausch Health Companies (BHC) over the last 17 years, with Q3 2025 value amounting to $619.0 million.

  • Bausch Health Companies' EBITDA rose 9465.41% to $619.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 4051.85%. This contributed to the annual value of $1.5 billion for FY2024, which is 6054.0% up from last year.
  • According to the latest figures from Q3 2025, Bausch Health Companies' EBITDA is $619.0 million, which was up 9465.41% from $444.0 million recorded in Q2 2025.
  • Bausch Health Companies' EBITDA's 5-year high stood at $619.0 million during Q3 2025, with a 5-year trough of -$270.0 million in Q2 2021.
  • For the 5-year period, Bausch Health Companies' EBITDA averaged around $250.1 million, with its median value being $285.0 million (2022).
  • Within the past 5 years, the most significant YoY rise in Bausch Health Companies' EBITDA was 744000.0% (2021), while the steepest drop was 90000.0% (2021).
  • Over the past 5 years, Bausch Health Companies' EBITDA (Quarter) stood at $367.0 million in 2021, then crashed by 164.31% to -$236.0 million in 2022, then skyrocketed by 253.39% to $362.0 million in 2023, then surged by 54.14% to $558.0 million in 2024, then increased by 10.93% to $619.0 million in 2025.
  • Its EBITDA stands at $619.0 million for Q3 2025, versus $444.0 million for Q2 2025 and $276.0 million for Q1 2025.